Cargando…

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

AIM: We analyzed the association between the modified albumin–bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) for the treatment of unresectable hepatocellular carcinoma (u‐HCC). METHODS: In this retrospective observational study, we included 71 u‐HCC pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tomonari, Tetsu, Tani, Joji, Sato, Yasushi, Tanaka, Hironori, Tanaka, Takahiro, Taniguchi, Tatsuya, Asahiro, Morishita, Okamoto, Koichi, Sogabe, Masahiro, Miyamoto, Hiroshi, Muguruma, Naoki, Masaki, Tsutomu, Takayama, Tetsuji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939118/ https://www.ncbi.nlm.nih.gov/pubmed/35964253 http://dx.doi.org/10.1002/cam4.5145

Ejemplares similares

Clinical Features and Outcomes of Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2023)

Sorafenib as second‐line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Conversion therapy for unresectable hepatocellular carcinoma after lenvatinib: Three case reports
por: Tomonari, Tetsu, et al.
Publicado: (2020)

Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array
por: Tomonari, Tetsu, et al.
Publicado: (2020)

An Adult Case of Congenital Extrahepatic Portosystemic Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration
por: Tanaka, Hironori, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome
por: Sogabe, Masahiro, et al.
Publicado: (2016)

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2016)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
por: Takehara, Masanori, et al.
Publicado: (2021)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

APOB codon 4311 polymorphism is associated with hepatitis C virus infection through altered lipid metabolism
por: Harada, Rie, et al.
Publicado: (2018)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

MiR-125b-5p Is Involved in Sorafenib Resistance through Ataxin-1-Mediated Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma
por: Hirao, Akihiro, et al.
Publicado: (2021)

Influence of Alcohol Consumption on the Development of Erosive Esophagitis in Both Sexes: A Longitudinal Study
por: Sogabe, Masahiro, et al.
Publicado: (2022)

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Matsumoto, Hiroaki, et al.
Publicado: (2022)

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021)

A case of unresectable combined hepatocellular and cholangiocarcinoma treated with atezolizumab plus bevacizumab
por: Saito, Naoto, et al.
Publicado: (2022)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Comparison of the role of alcohol consumption and qualitative abdominal fat on NAFLD and MAFLD in males and females
por: Sogabe, Masahiro, et al.
Publicado: (2022)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

Diaphragmatic Hernia after Radiofrequency Ablation
por: Morishita, Asahiro, et al.
Publicado: (2021)

Unusual pedunculated gastric polypoid lesion
por: Morishita, Asahiro, et al.
Publicado: (2020)

Differences among patients with and without nonalcoholic fatty liver disease having elevated alanine aminotransferase levels at various stages of metabolic syndrome
por: Sogabe, Masahiro, et al.
Publicado: (2020)

Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study
por: Sogabe, Masahiro, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab-induced intratumoral hemorrhage in a patient with rib metastasis from unresectable hepatocellular carcinoma
por: Mitsuyama, Yasuhito, et al.
Publicado: (2023)

The differing influence of several factors on the development of fatty liver with elevation of liver enzymes between genders with metabolic syndrome: A cross-sectional study
por: Sogabe, Masahiro, et al.
Publicado: (2017)

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
por: Sho, Takuya, et al.
Publicado: (2022)

Cost-utility analysis of atezolizumab with bevacizumab in untreated unresectable or advanced hepatocellular carcinoma in France
por: Gaugain, Loïg, et al.
Publicado: (2023)

Two cases of unresectable hepatocellular carcinoma treated via atezolizumab and bevacizumab combination therapy
por: Tsunemitsu, Ryosuke, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Effects of audio and visual distraction on patients’ vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial
por: Sogabe, Masahiro, et al.
Publicado: (2020)

Risk Factors for Early Onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Ando, Yuwa, et al.
Publicado: (2022)

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
por: Oura, Kyoko, et al.
Publicado: (2021)

Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
por: Oura, Kyoko, et al.
Publicado: (2022)

Therapeutic Modifications without Discontinuation of Atezolizumab Plus Bevacizumab Therapy Are Associated with Favorable Overall Survival and Time to Progression in Patients with Unresectable Hepatocellular Carcinoma
por: Tokunaga, Takayuki, et al.
Publicado: (2023)

Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma
por: Kosaka, Yumi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7v17pc9296fkcgq3tt43qfhhbb